Best first cycles in 2026 — 10 beginner protocols ranked

1. 1. Test E 500 mg/wk solo for 12 wk — the classic starter

   The universal reference protocol for a first cycle. Testosterone enanthate alone, moderate dose (500 mg/wk), standard duration (12 weeks). No experimental molecule or complex stack — maximum predictability to identify individual response to androgens. Expected gains: +4 to +7 kg lean mass for a natural-ceiling user with optimized training and nutrition (Bhasin 1996 baseline). Classic Nolvadex PCT. HPG recovery documented in 3-4 months (Smit 2021).

   Dose / Duration

   Test enanthate 500 mg/wk in 2 injections (Mon 250 mg / Thu 250 mg) for 12 wk. AI only if needed (E2 >60 pg/mL or gyno symptoms mid-cycle). PCT Nolvadex 40/40/20/20 mg/d for 4 wk, starting W+2 wk post-last injection.

   Target audience

   Universal first cycle. Men 25-40, natural FFMI >=24, 3-4 years of serious training, solid baseline bloodwork (total T >450 ng/dL, normal LH, good lipids), no history of gynecomastia or premature alopecia.

   Pros

   • + Solid scientific reference (Bhasin 1996 NEJM)
   • + Well-documented and predictable side-effect profile
   • + Simple and economical PCT
   • + Fast HPG recovery (3-4 months)
   • + Very accessible total cost (~$150 cycle + PCT)
   • + Reliable, widely available black-market source

   Cons

   • − Marked aromatization — possible gynecomastia if AI poorly managed
   • − Back acne and accelerated balding depending on genetics
   • − Visible water retention (4-6% of weight)
   • − Inevitable HPG suppression (but recoverable)
   • − Modest gains vs advanced cycles

2. 2. Test E 400 mg/wk solo for 10 wk — the cautious starter

   'Ultra-conservative' variant: reduced dose (400 mg/wk) and short duration (10 wk) to minimize HPG suppression and facilitate recovery. Expected gains +3 to +5 kg lean mass, but optimal safety profile. Suited to young users (25-28) or with specific concerns (HPG, fertility, ASIH). HPG recovery documented in 2-3 months.

   Dose / Duration

   Test enanthate 400 mg/wk in 2 inj (200 mg Mon/Thu) for 10 wk. AI only if needed. PCT Nolvadex 40/40/20/20 for 4 wk.

   Target audience

   Young men (25-28), unknown HPG genetics, fertility concerns, 'tolerance test' first cycle, or users seeking to minimize health impact for a controlled first attempt.

   Pros

   • + Minimized HPG suppression
   • + Fast recovery (2-3 months)
   • + Reduced side-effect risk
   • + Better preserved lipid profile
   • + "Personal tolerance test" cycle before subsequent cycles

   Cons

   • − More modest gains (+3 to +5 kg)
   • − Gain/risk ratio sometimes deemed sub-optimal
   • − Kinetic plateau reached late (W5-W6)
   • − Not suited if massive gain goal
   • − May frustrate user having exhausted natural potential

3. 3. Test cypionate 500 mg/wk for 12 wk — the US equivalent

   Strictly equivalent to Test E (Schulte-Beerbühl 1980: both esters have nearly superimposable pharmacokinetics, 4-5 day half-lives). More available in the USA and Latin America, less in Europe (Test E more common). Choose based on local availability.

   Dose / Duration

   Test cypionate 500 mg/wk in 2 inj for 12 wk. AI as needed. PCT Nolvadex 40/40/20/20 for 4 wk.

   Target audience

   Users in North America or with a Test C-oriented supplier, profile and indications strictly identical to Test E.

   Pros

   • + Strictly equivalent to Test E (Schulte-Beerbühl 1980)
   • + USA reference
   • + Equivalent tolerance
   • + Identical PCT
   • + Concentration often 200 mg/ml (vs 250 mg/ml Test E)

   Cons

   • − Lower Europe availability
   • − No practical difference vs Test E
   • − Regional preference rather than technical choice
   • − Same risks as Test E
   • − Slightly higher injection volume if 200 mg/ml

4. 4. Sustanon 250 x 500 mg/wk for 12 wk — the classic ester mix

   Mix of 4 testosterone esters (propionate 30 mg, phenylpropionate 60 mg, isocaproate 60 mg, decanoate 100 mg per 250 mg ampoule). Theoretically, more gradual and stable release. In practice, comparable to Test E in 2 injections/wk. Advantage in France: Sustanon 250 (Aspen) sometimes available at retail pharmacy under ATU or off-label prescription.

   Dose / Duration

   Sustanon 250: 500 mg/wk (2 amp 250 mg, Mon/Thu) for 12 wk. AI as needed. PCT Nolvadex 40/40/20/20 for 4 wk.

   Target audience

   Users in France with Sustanon pharmacy access, or with a reliable UGL source. Classic first cycle alternative to pure Test E.

   Pros

   • + Ester mix: smoother ramp, fewer peaks
   • + Sustanon Aspen pharmacy: guaranteed quality
   • + Good comfort/efficacy compromise
   • + Tolerance profile equivalent to Test E
   • + Very popular — much user feedback

   Cons

   • − Short esters (propionate, phenylpropionate) sometimes irritating
   • − Higher pharmacy Sustanon Aspen cost (~$80-120 vs $40 UGL)
   • − No clinical benefit vs pure Test E in practice
   • − If UGL Sustanon: decanoate sometimes under-dosed (expensive to produce)
   • − Complex PCT timing (esters of varied durations)

5. 5. Test E 500 mg/wk + Anavar 30 mg/d (wk 6-12) — the "start + finish"

   Variant adding Anavar in the second half of cycle, for improved aesthetic profile. Anavar (oxandrolone) at moderate dose 30 mg/d for last 6 weeks brings 'hardness' and vascularity without retention. Strawford 1999 documents the modest but real anabolic effect of oxandrolone at 20 mg/d. Moderate liver risk (17α-alkylated).

   Dose / Duration

   Test enanthate 500 mg/wk for 12 wk + Anavar 30-40 mg/d for W6-W12. AI as needed. Hepatoprotectors W6-W12 (TUDCA, NAC). PCT Nolva 40/40/20/20.

   Target audience

   First cycle for users with aesthetic ambition (fitness model, photoshoot), solid baseline liver and lipids, reliable Anavar sources. Not if baseline HDL <45.

   Pros

   • + Improved aesthetic profile at finish
   • + Anavar anti-catabolic effect (Strawford 1999)
   • + Visible vascularity at W10-W12
   • + Moderate Anavar dose — limited liver risk
   • + Good first-cycle option with aesthetic ambition

   Cons

   • − Adding a 17α-alkylated oral on first cycle
   • − Degraded lipid profile under Anavar (HDL -30%)
   • − High Anavar cost (~$150 for 6 wk)
   • − Black-market Anavar: frequent counterfeits
   • − Increased load on first cycle

6. 6. Test E + Dbol kickstart (40 mg/d for 4 wk) — the first "rapid cycle"

   'Kickstart' variant: Dianabol 30-40 mg/d for first 4 weeks for rapid gains during long-ester ramp. Visible gains from W2-W3, amplified motivation. Considered an 'advanced' first cycle: adds hepatotoxicity (17α-alkylated Dbol) and marked water retention. Hartgens 2004 documents lipid degradation under Dbol.

   Dose / Duration

   Test enanthate 500 mg/wk for 12 wk + Dianabol 30-40 mg/d during W1-W4 (kickstart). AI mandatory from W2 (anastrozole 0.5 mg E2D). Hepatoprotectors W1-W4. Classic PCT.

   Target audience

   First cycle only if user previously did a SARMs cycle, excellent baseline liver and lipids, young (25-30), no hypertension. Not as absolute first cycle if naive.

   Pros

   • + Visible gains from W2-W3
   • + Motivation amplified by rapid effect
   • + PR strength effect during kickstart
   • + Perfect kinetic synergy with long ester
   • + Moderate cost (accessible UGL Dbol)

   Cons

   • − Dbol hepatotoxicity (Niedfeldt 2018)
   • − Heavy water retention (puffy face, smooth skin)
   • − Elevated blood pressure (Hartgens 2004)
   • − Loss of some gains when stopping Dbol
   • − "Heavy" first cycle — difficult adaptation for follow-up

7. 7. Test E 500 mg/wk + Proviron 50 mg/d — the "E2/SHBG-optimized" cycle

   Variant with Proviron (mesterolone) 50 mg/d, a DHT-derivative that modulates SHBG (frees free testosterone) and has a modest antiestrogenic effect. WHO 1989 documents mesterolone efficacy in specific indications. No significant direct anabolic effect, but improves cycle's subjective quality (libido, muscle fullness sensation).

   Dose / Duration

   Test enanthate 500 mg/wk for 12 wk + Proviron 25-50 mg/d for 8-12 wk. AI rarely needed (Proviron modulates SHBG). Classic Nolva PCT.

   Target audience

   First cycle for users sensitive to subjective quality (libido priority), high baseline SHBG, or seeking an 'optimized' cycle without additional liver load.

   Pros

   • + Modulates SHBG, increases available free T
   • + Mild antiestrogenic effect (little AI needed)
   • + Improves cycle's subjective quality (libido, energy)
   • + Not hepatotoxic
   • + Little retention

   Cons

   • − Minimal direct anabolic effect
   • − Additional cost (~$50-100 for 8 wk)
   • − Black-market Proviron: frequent counterfeits
   • − Variable availability
   • − Not essential for first cycle

8. 8. Sustanon 250 + Boldenone 400 mg/wk for 14 wk — the "slow and clean" cycle

   Variant oriented toward gain quality: Sustanon (testosterone base) + Boldenone undecylenate (very long ester, low aromatization). Clean aesthetic profile, low retention. Long cycle (14-16 wk) since boldenone takes 7-8 wk to reach its serum plateau. Increased erythrocytosis (improved endurance). 'Ambitious' first cycle.

   Dose / Duration

   Sustanon 250: 500 mg/wk + Boldenone undecylenate 400 mg/wk for 14-16 wk. AI as needed. Hematocrit monitoring W6 and W12. Classic PCT with recommended pre-PCT hCG.

   Target audience

   'Ambitious' first cycle for users >28 with SARMs experience, solid baseline cardiovascular, availability for long cycle. Not for absolute first cycle if naive.

   Pros

   • + Clean aesthetic profile (little retention)
   • + Low aromatization of boldenone
   • + Marked appetite effect (useful in caloric surplus)
   • + Improved endurance (erythrocytosis)
   • + Good overall tolerance

   Cons

   • − Long cycle mandatory (14-16 wk)
   • − Elevated hematocrit to monitor (>54% = phlebotomy)
   • − Higher cost (Boldenone volumes)
   • − Black market: Boldenone often under-dosed
   • − More demanding PCT (long cycle)

9. 9. Ostarine 25 mg/d for 8 wk (SARM) — the "light first cycle"

   Non-AAS first cycle: Ostarine (MK-2866), a partial agonist SARM at the androgen receptor. Dalton 2011 documents +1.3 kg lean mass in 12 wk at 3 mg/d in elderly subjects; in bodybuilders at 25 mg/d, expected gains +2-4 kg with moderate HPG suppression (Bhasin 2009). PCT required (Nolva 20 mg/d for 4 wk). Not the 'natural bridge' often sold — really suppresses the HPG axis.

   Dose / Duration

   Ostarine 25 mg/d (single morning dose) for 8 wk. PCT Nolvadex 20 mg/d for 4 wk, start D+3 post-last dose. Mid-cycle total T + LH bloodwork.

   Target audience

   Users hesitating to switch to AAS injections, seeking a 'light' first protocol with modest gains. Do not consider it a 'non-cycle' — PCT required.

   Pros

   • + "Light" first cycle without injection
   • + Modest but real anabolic effect (Dalton 2011)
   • + Joint preservation (collagen)
   • + No aromatization, no DHT
   • + Moderate cost (~$80-150 depending on source)

   Cons

   • − Black-market SARMs: highly variable quality
   • − Significant HPG suppression at 25 mg/d (myth of "non-suppressive")
   • − Limited human clinical studies
   • − Unclear legal status (research chemical, WADA-banned)
   • − Minor but documented liver risk

10. 10. Test E 500 mg/wk + Turinabol 40 mg/d for 6 wk — the "light kickstart"

    Intermediate variant between Test E solo and Test E + Dbol: Turinabol (chlorodehydromethyltestosterone, oral ester) at 40 mg/d for 6 wk as kickstart. Less hepatotoxic than Dbol/Anadrol, low aromatization, low retention. Sobolevsky 2012 documented its long-term metabolites (anti-doping detection up to 12-18 months). 'Clean' oral profile.

    Dose / Duration

    Test enanthate 500 mg/wk for 12 wk + Turinabol 40 mg/d during W1-W6. AI as needed. Hepatoprotectors W1-W6. Classic PCT.

    Target audience

    First cycle for users wanting an oral kickstart without maximum load, solid baseline liver, 'clean' athletic profile. Not for tested athletes (very long detection).

    Pros

    • + Oral milder than Dbol (less hepatotoxic)
    • + Little aromatization, little retention
    • + Clean visual gains
    • + Kickstart effect without excess water retention
    • + Moderate cost

    Cons

    • − Moderate hepatotoxicity (17α-alkylated)
    • − Degraded lipid profile
    • − Very long anti-doping detection (Sobolevsky 2012)
    • − Black-market UGL: frequent counterfeits
    • − Raw muscle gains lower than Dbol